{"id":40882,"date":"2025-09-08T14:47:52","date_gmt":"2025-09-08T06:47:52","guid":{"rendered":"https:\/\/flcube.com\/?p=40882"},"modified":"2025-09-08T14:47:52","modified_gmt":"2025-09-08T06:47:52","slug":"takeda-secures-fda-approval-for-vonvendis-expanded-use-in-adult-and-pediatric-vwd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40882","title":{"rendered":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD"},"content":{"rendered":"\n<p>Japan-based Takeda Pharmaceutical (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for <strong>VONVENDI<\/strong> (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-this-means-for-vwd-treatment\">What This Means for VWD Treatment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Adults<\/strong> \u2013 Routine prophylaxis now available for Type\u202f1 and\u202f2 VWD, in addition to the previously approved on\u2011demand and peri\u2011operative uses.<\/li>\n\n\n\n<li><strong>Children<\/strong> \u2013 VONVENDI can now be used for on\u2011demand and peri\u2011operative bleeding control.<\/li>\n\n\n\n<li><strong>Severe Type\u202f3 VWD<\/strong> \u2013 Continues to receive routine prophylaxis for adults on an on\u2011demand basis.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-basis\">Scientific Basis<\/h3>\n\n\n\n<p>The expanded indication is underpinned by robust evidence from three Phase\u202f3 programs:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>NCT02973087<\/strong> \u2013 Adults with VWD.<\/li>\n\n\n\n<li><strong>NCT02932618<\/strong> \u2013 Children with VWD.<\/li>\n\n\n\n<li><strong>NCT03879135<\/strong> \u2013 Phase\u202f3b continuation in adults and children.<\/li>\n<\/ol>\n\n\n\n<p>Real\u2011world data further demonstrate VONVENDI\u2019s effectiveness in controlling bleeding episodes and supporting peri\u2011operative care across all age groups.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-company-perspective\">Company Perspective<\/h3>\n\n\n\n<p>Takeda\u2019s leadership highlighted the milestone as a \u201csignificant step forward in providing comprehensive, life\u2011changing treatment for patients with VWD.\u201d The company also noted that the approval will enhance global access to a proven, recombinant VWF replacement therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-and-regulatory-impact\">Market and Regulatory Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Broader Patient Reach<\/strong> \u2013 The expanded indications increase the potential patient population by covering both adult Type\u202f1\/2 disease and pediatric care.<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong> \u2013 VONVENDI\u2019s expanded approval strengthens Takeda\u2019s foothold in the bleeding disorder market, where limited therapeutic options remain.<\/li>\n\n\n\n<li><strong>Future Outlook<\/strong> \u2013 Takeda plans to pursue additional indications, including extended\u2011release formulations and global market entry in regions with high unmet VWD needs.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h3>\n\n\n\n<p>Takeda\u2019s FDA approval of VONVENDI\u2019s expanded use marks a pivotal moment for VWD therapy, offering broader prophylactic and peri\u2011operative options for adults and children alike while reinforcing the company\u2019s leadership in rare\u2011disease therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[874,15,345,1141],"class_list":["post-40882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-tak","tag-product-approvals","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD\" \/>\n<meta property=\"og:description\" content=\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40882\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T06:47:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD\",\"datePublished\":\"2025-09-08T06:47:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0806.webp\",\"keywords\":[\"NYSE: TAK\",\"Product approvals\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40882#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40882\",\"name\":\"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0806.webp\",\"datePublished\":\"2025-09-08T06:47:52+00:00\",\"description\":\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD - Insight, China&#039;s Pharmaceutical Industry","description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40882","og_locale":"en_US","og_type":"article","og_title":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD","og_description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.","og_url":"https:\/\/flcube.com\/?p=40882","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-08T06:47:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40882#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40882"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD","datePublished":"2025-09-08T06:47:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40882"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","keywords":["NYSE: TAK","Product approvals","Takeda","TYO: 4502"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40882#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40882","url":"https:\/\/flcube.com\/?p=40882","name":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40882#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","datePublished":"2025-09-08T06:47:52+00:00","description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI (von Willebrand factor, recombinant). The approval expands the drug\u2019s use to routine prophylaxis in adults with von\u202fWillebrand disease (VWD) Types\u202f1 and\u202f2, and to on\u2011demand and peri\u2011operative bleeding management in pediatric patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40882#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","width":1080,"height":608,"caption":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Secures FDA Approval for VONVENDI\u2019s Expanded Use in Adult and Pediatric VWD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40882"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40882\/revisions"}],"predecessor-version":[{"id":40885,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40882\/revisions\/40885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40884"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}